Literature DB >> 33519429

Dihydropyridine Calcium Channel Blockers Suppress the Transcription of PD-L1 by Inhibiting the Activation of STAT1.

Xiaohui Pan1, Run Li2, Hongjie Guo1, Wenxin Zhang1, Xiaqing Xu1, Xi Chen1, Ling Ding1.   

Abstract

Programmed death ligand 1 (PD-L1) which is upregulated in various epithelial tumors, plays a central role in the evasion of the immune system. In addition to monoclonal antibodies that blocking PD1/PD-L1 axis, finding small molecule compounds that can suppress PD-L1 expression might be another substitutable strategy for PD1/PD-L1 based therapy. Here, we found that dihydropyridine calcium channel blockers dose-dependently reduced the expression of PD-L1, both in the cytoplasm and cell surface. IFNγ induced PD-L1 transcription was consistently suppressed by Lercanidipine in 24 h, whereas, the half-life of PD-L1 protein was not significantly affected. IFNγ trigged significant STAT1 phosphorylation, which was eliminated by Lercanidipine. Similarly, STAT1 phosphorylation could also be abolished by extracellular calcium chelating agent EGTA and intracellular calcium chelator BAPTA-AM. Furthermore, Lercanidipine enhanced killing ability of T cells by down-regulating PD-L1. Taken together, our studies suggest that calcium signal is a crucial factor that mediates the transcription of PD-L1 and regulation of calcium can be used as a potential strategy for PD-L1 inhibition.
Copyright © 2021 Pan, Li, Guo, Zhang, Xu, Chen and Ding.

Entities:  

Keywords:  NSCLC; PD-L1; STAT1; dihydropyridine calcium channel blockers; transcription

Year:  2021        PMID: 33519429      PMCID: PMC7838064          DOI: 10.3389/fphar.2020.539261

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  3 in total

1.  Bafetinib Suppresses the Transcription of PD-L1 Through c-Myc in Lung Cancer.

Authors:  Xi Chen; Qianqian Du; Hongjie Guo; Qiaojun He; Bo Yang; Ling Ding
Journal:  Front Pharmacol       Date:  2022-06-02       Impact factor: 5.988

Review 2.  Drug Repurposing to Enhance Antitumor Response to PD-1/PD-L1 Immune Checkpoint Inhibitors.

Authors:  Xavier Thuru; Romain Magnez; Hassiba El-Bouazzati; Gérard Vergoten; Bruno Quesnel; Christian Bailly
Journal:  Cancers (Basel)       Date:  2022-07-11       Impact factor: 6.575

Review 3.  Mitochondrial adaptation in cancer drug resistance: prevalence, mechanisms, and management.

Authors:  Ping Jin; Jingwen Jiang; Li Zhou; Zhao Huang; Edouard C Nice; Canhua Huang; Li Fu
Journal:  J Hematol Oncol       Date:  2022-07-18       Impact factor: 23.168

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.